Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Sickle cell anemia (SCA) is a well characterized severe hematological disorder with substantial morbidity and early mortality. Hydroxyurea is a potent inducer of fetal hemoglobin, and evidence over the past 25 years has documented its laboratory and clinical efficacy for both adults and children with SCA. RECENT FINDINGS: The phase III study of hydroxyurea in infants (BABY HUG) has just been completed and preliminary results indicate equivocal benefits for organ protection during the 2-year treatment period, but significant benefits for pain, acute chest syndrome, hospitalizations, and transfusions. Three new reports document the benefits of hydroxyurea on reducing mortality in SCA: two adult trials (LaSHS and MSH) and one pediatric study (Brazilian cohort). Recent results from the HUSTLE protocol suggest minimal genotoxicity or carcinogenicity with long-term hydroxyurea exposure. SUMMARY: The potential utility of hydroxyurea for all patients with SCA is clear and indisputable. With decades of accumulated evidence and documented efficacy with an acceptable long-term safety profile, it is time to consider hydroxyurea treatment the standard of care for all young patients with SCA. Exporting our knowledge and experience with hydroxyurea to developing nations with large medical burdens from SCA can help relieve global suffering from this condition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Outcome of Sickle Cell Anemia: A 4-Decade Observational Study of 1056 Patients
Powars, D. R., Chan, L. S., Hiti, A., Ramicone, E., & Johnson, C. (2005) · Medicine · doi:10.1097/01.md.0000189089.45003.52 · Cited by 558
Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D., & Terpos, E. (2010) · Blood · doi:10.1182/blood-2009-05-221333 · Cited by 430
Cited by
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies
Manwani, D., & Frenette, P. S. (2013) · Blood · doi:10.1182/blood-2013-05-498311 · Cited by 428
“Hydroxyurea is a potent inducer of HbF, and evidence over the past 25 years has documented its laboratory and clinical efficacy for both adults and children with SCD.28 Given its indisputable efficacy in responders, current efforts are directed toward expanding its utilization in both developed and developing nations.”
BackgroundInfluentialZhang, D., Xu, C., Manwani, D., & Frenette, P. S. (2016) · Blood · doi:10.1182/blood-2015-09-618538 · Cited by 413
“Hydroxyurea, the only FDA-approved therapy for SCD, is a potent inducer of HbF.106 However, hydroxyurea has multiple mechanisms by which it produces its clinical response.”
BackgroundMaitra, P., Caughey, M., Robinson, L., Desai, P. C., Jones, S., Nouraie, M., Gladwin, M. T., Hinderliter, A., Cai, J., & Ataga, K. I. (2017) · Haematologica · doi:10.3324/haematol.2016.153791 · Cited by 137
da Silva Junior, G. B., Libório, A. B., & De Francesco Daher, E. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1327-8 · Cited by 34
Alagbe, A. E., Justo Junior, A. S., Ruas, L. P., Tonassé, W. V., Santana, R. M., Batista, T. H. C., Domingos, I. F., Araujo, A. S., Bezerra, M. A. C., Santos, M. N. N., et al. (2018) · Cytokine · doi:10.1016/j.cyto.2017.12.001 · Cited by 20
Metadata
- Authors
- McGann, P. T., & Ware, R. E.
- Venue
- Current Opinion in Hematology
- Published
- 2011-05
- Volume
- 18
- Issue
- 3
- Pages
- 158-165
- ISSN
- 1065-6251 (ISSN-L)
- OpenAlex
- W2074901521
- Cited by
- 156
- References
- 4
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? https://app.cochat.ai/papers/10.1097/moh.0b013e32834521dd
- The paper
- McGann, P. T., & Ware, R. E. (2011). Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Current Opinion in Hematology. https://doi.org/10.1097/moh.0b013e32834521dd
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.